Stock listing

NASDAQ:SGP SpyGlass Pharma, Inc. Stock

Home listing (NASDAQ) of SpyGlass Pharma, Inc.

Follow SpyGlass Pharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SGP

$30.43 USD +0.75 (+2.5%)

Close on Nov 20, 2026

Since Feb 6, 2026 +15.3% · daily closes, Feb 6, 2026 – Nov 20, 2026, adjusted for splits
Day range
$29.60 – $31.73 USDNov 20, 2026
Volume
108,909 sharesNov 20, 2026
Market cap
$1.02B USDAt the close on Nov 20, 2026 · price × 33.46M shares outstanding
Traded on an average day
$3.32M USDMedian day 89,398 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
SpyGlass Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SGP · Home$30.43 USD+0.75 (+2.5%)108,909$30.12$31.73$29.60$29.68Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SGP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$30.43+0.75+2.5%$30.12$31.73$29.60108,909
$29.68-1.755-5.6%$31.44$31.95$29.1095,000
$31.44-0.805-2.5%$32.09$32.81$30.5388,099
$32.24-0.64-1.9%$32.48$32.81$29.16246,130
$32.88-0.44-1.3%$33.88$33.88$32.1239,457
$33.32-1.65-4.7%$35.68$35.68$33.1554,414
$34.97+0.79+2.3%$33.52$35.53$33.2577,564
$34.18-4.19-10.9%$38.00$38.00$33.7194,126
$38.37+1.425+3.9%$37.59$39.92$36.90227,011
$36.95+2.865+8.4%$34.50$37.12$33.93109,374
$34.08-0.37-1.1%$34.61$34.61$32.00191,964
$34.450.000.0%$35.07$35.75$33.51201,017
$34.45+0.81+2.4%$34.08$35.15$34.08191,537
$33.64+1.40+4.3%$32.71$33.96$31.6094,805
$32.24-0.27-0.8%$32.21$32.93$31.7594,146
$32.51-0.35-1.1%$33.12$33.84$31.68125,359
$32.86+1.96+6.3%$30.90$33.47$30.03211,716
$30.90+0.99+3.3%$30.01$31.06$29.4169,335
$29.91+1.43+5.0%$29.21$30.35$28.0989,398
$28.48+0.26+0.9%$28.00$28.70$26.6870,600
$28.22+0.51+1.8%$27.43$28.30$27.3391,300
$27.71+1.55+5.9%$26.52$27.73$26.0486,100
$26.16+1.56+6.3%$24.49$26.67$23.2899,400
$24.60+0.60+2.5%$24.36$25.15$24.3469,800
$24.00-0.72-2.9%$24.74$24.84$23.9470,600
$24.72+1.03+4.3%$23.67$24.93$23.5047,100
$23.69-0.23-1.0%$23.72$24.21$22.8049,100
$23.92-0.94-3.8%$24.53$24.85$23.8963,900
$24.86-0.06-0.2%$24.60$25.54$24.1459,500
$24.92+0.30+1.2%$25.03$25.79$24.6368,300
$24.62+0.72+3.0%$23.56$24.84$23.2964,600
$23.90-0.88-3.6%$24.46$24.76$23.6269,500
$24.78-0.81-3.2%$25.76$25.87$24.7581,200
$25.59+0.67+2.7%$24.78$25.71$24.60133,100
$24.92-1.58-6.0%$26.73$27.11$24.68142,100
$26.50+0.50+1.9%$26.30$26.81$25.34101,100
$26.00+0.56+2.2%$25.44$26.52$25.0579,600
$25.44-0.54-2.1%$25.84$26.25$24.4067,900
$25.98-1.09-4.0%$26.97$27.26$25.98120,000
$27.07-0.58-2.1%$27.51$27.92$26.8596,400
$27.65-0.51-1.8%$28.22$28.22$26.6481,400
$28.16-0.53-1.8%$28.99$29.28$27.76149,300
$28.69+0.73+2.6%$27.98$29.07$27.85171,700
$27.96-1.12-3.9%$29.40$29.96$27.29174,300
$29.08-0.25-0.9%$29.25$29.47$27.33613,800
$29.33+0.73+2.6%$29.12$29.75$28.62235,600
$28.60-0.36-1.2%$29.21$29.41$27.13186,200
$28.96+0.30+1.0%$28.57$29.04$27.00131,700
$28.66+1.14+4.1%$27.56$28.75$27.56130,200
$27.52+0.21+0.8%$27.68$28.40$27.29169,500
$27.31-0.19-0.7%$27.06$28.00$27.0183,600
$27.50-1.42-4.9%$28.77$29.17$27.0978,400
$28.92-0.02-0.1%$28.64$30.05$27.82119,400
$28.94-0.05-0.2%$28.81$29.18$28.0375,100
$28.99+0.71+2.5%$28.52$29.25$28.2882,800
$28.28+1.42+5.3%$26.95$28.74$26.95113,500
$26.86+0.76+2.9%$25.25$27.00$25.2587,100
$26.10-0.32-1.2%$26.42$26.66$25.5364,800
$26.42-0.51-1.9%$27.00$27.10$26.0089,800
$26.93+0.29+1.1%$26.65$27.39$26.3566,000
$26.64+0.04+0.2%$26.63$26.92$25.8674,500
$26.60+0.34+1.3%$26.45$26.93$26.1660,332
$26.26-0.25-0.9%$26.48$26.58$25.7270,133
$26.51+0.28+1.1%$26.55$27.44$26.2752,300
$26.23-1.00-3.7%$27.01$27.06$26.0060,100
Ticker
NASDAQ:SGP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All SpyGlass Pharma, Inc. news

SpyGlass Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 16 in all · newest Nov 11, 2026 · oldest 2026
Decks
2 decks · latest August 2026

Where SpyGlass Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SGP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SGPBOATSUnited StatesUSD

Valuation

Price/book 4.8× against a median of 4.0×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$809.5M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
4.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.01

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
SpyGlass Pharma, Inc. · NASDAQ:SGPUS$1.02BUS$809.5Mn/an/an/a4.8×n/a0.0×1.01
MedinCell SA · EURONEXT:MEDCLUS$1.05BUS$1.02Bn/a38.4×n/a313×−128.9%18.7×n/a
Nektar Therapeutics · NASDAQ:NKTRUS$1.03BUS$492.8Mn/a9.4×n/a1.2×−339.7%0.1×1.28
Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062US$1.02BUS$984.8Mn/a9.2×n/a9.5×−146.4%2.9×n/a
Alto Neuroscience, Inc. · NYSE:ANROUS$1.02BUS$711.7Mn/an/an/a3.4×n/a0.1×1.65
Inhibrx Biosciences, Inc. · NASDAQ:INBXUS$1.02BUS$1.09Bn/a546×n/an/an/an/a1.89
Duality Biotherapeutics, Inc. · HKEX:9606US$992.3MUS$609.0Mn/a4.8×n/a4.6×−170.8%0.3×n/a
Peptron, Inc. · KRX:087010US$985.3MUS$948.0Mn/a211×n/a10.2×−342.2%0.2×n/a
Omeros Corporation · NASDAQ:OMERUS$983.7MUS$920.3M10.0×12.4×n/an/a132.3%n/a1.64
Everest Medicines Ltd. · HKEX:1952US$981.5MUS$1.00Bn/a2.8×183×1.3×−2.2%0.4×n/a
HBM Holdings Ltd. · HKEX:2142US$981.4MUS$711.5M10.7×4.5×8.6×2.4×57.8%0.2×n/a
Median of the othersUS$1.00BUS$934.1M10.4×9.4×95.9×4.0×−137.6%0.2×1.65

Forecasts

5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
46.33 USD · Analysts' mean
EPS, year to Dec 2026
-2.77 · 4 analysts

Team and board

Officers

OfficerRole
Patrick MooneyChief Executive Officer
Brian AukshunasVice President, Finance
Jean-Frédéric ViretChief Financial Officer
Malik Y. KahookCo-founder, President, Chief Medical Officer, and Executive Chair of the Board
James DennewillChief Operating Officer
Shannon TreviñoGeneral Counsel
Anand SundaramVice President, Head of Commercial
Laurie MellottVice President, Clinical Operations
Mike PinderVice President, Marketing
Nina NguyenSenior Vice President, Regulatory & Quality
Paul YooSenior Vice President, Clinical Development
Rachel GiletteVice President, Human Resources
Chetan PujaraChief Research and Development Officer

Board

DirectorRole
Malik Y. KahookCo-founder, President, Chief Medical Officer, and Executive Chair of the Board

Events

QuarterResultsShare move
Q3 2026Nov 11, 2026 · After close−4.7%
Q2 2026Aug 6, 2026 · After close+2.3%
Q1 2026May 14, 2026 · After close−4.4%
Q4 2025Mar 27, 2026−7.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck33 slidesAugust 2026
Interventional Glaucoma Consortium (IGC) Meeting 2025Conference14 slidesNov 8, 2025

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$172.5M raised · US$16 a share · Jefferies +3
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Stifel (co-lead)
Feb 9, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Feb 5, 2026.

Price
US$16.00 a share
Shares offered
9,375,000 shares of common stock
Offering size
US$150 million
Underwriters' option
Up to 1,406,250 more shares
Listing
SGP on the Nasdaq Global Select Market
Underwriters
Jefferies, Leerink Partners, Citigroup, Stifel · In the order on the cover
Shares delivered
On or about Feb 9, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceSep 26, 2025
Filed publiclyJan 16, 2026
Amended onceJan 29, 2026
Declared effective by the SECJan 30, 2026
Shares registered with an exchangeFeb 5, 2026
Final prospectus, with the priceFeb 6, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Feb 6, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023
Revenue000
Cost of revenue612.0K
Gross profit-612.0K
Research and development29.2M20.0M9.96M
Selling, general and administrative12.2M7.08M4.27M
Operating income-41.4M-27.1M-14.2M
Depreciation and amortization612.0K271.0K122.7K
EBITDA-40.8M-26.8M-14.1M
Income before tax-39.9M-29.2M-13.3M
Income tax00
Net income-39.9M-29.2M-13.3M
Earnings per share, basic-17.98-16.31-0.42
Earnings per share, diluted-17.98-16.31

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents96.4M16.3M15.8M
Short-term investments11.1M024.5M
Receivables431.0K
Current assets108.8M17.4M40.6M
Property, plant and equipment2.34M2.17M
Total assets115.9M23.3M41.1M
Accounts payable2.70M1.98M639.2K
Current liabilities8.58M7.79M1.59M
Total debt1.58M
Total liabilities10.2M11.2M74.1M
Shareholders' equity-98.8M-60.5M-33.0M
Shares outstanding2.20M2.20M31.9M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-32.7M-22.0M-12.3M
Capital spending-789.0K-1.99M-216.5K
Free cash flow-33.5M-24.0M-12.5M
Cash from investing-11.8M22.3M
Cash from financing124.6M185.0K39.8M
Share buybacks-1.45M0
Change in cash80.1M419.0K7.01M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 18, 2026Big-stake noticeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
8-K · Current reportOct 19, 2026Current reportSEC
8-K · Current reportOct 1, 2026Current reportSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
All 98 filings
FilingDateTypeFiled with
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 9, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
8-K · Current reportFeb 13, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4/A · Change in ownership, amendedFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeFeb 10, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
8-K · Current reportFeb 9, 2026Management or board changeSEC
S-8 · Registration statement for employee plansFeb 6, 2026Offer documentSEC
424B4 · ProspectusFeb 6, 2026Offer documentSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 5, 2026Insider tradeSEC
CERT · Exchange's certificate of listingFeb 5, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeFeb 5, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
CORRESP · Letter to the SECJan 29, 2026Other filingsSEC
CORRESP · Letter to the SECJan 29, 2026Other filingsSEC
CORRESP · Letter to the SECJan 29, 2026Other filingsSEC
S-1/A · Registration statement, amendedJan 29, 2026Offer documentSEC
UPLOAD · Letter from the SECJan 27, 2026Other filingsSEC
CORRESP · Letter to the SECJan 16, 2026Other filingsSEC
S-1 · Registration statementJan 16, 2026Offer documentSEC
UPLOAD · Letter from the SECJan 13, 2026Other filingsSEC
DRSLTR · Letter to the SEC with a draftDec 9, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedDec 9, 2025Offer documentSEC
UPLOAD · Letter from the SECDec 1, 2025Other filingsSEC
DRS · Draft registration statementSep 26, 2025Offer documentSEC
DJun 5, 2025Other filingsSEC
DJul 11, 2023Other filingsSEC
DJan 5, 2021Other filingsSEC
DJun 5, 2019Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from SpyGlass Pharma, Inc.’s releases · as of Nov 2, 2026

Common shares
33,461,450
Fully diluted
33,461,450

Fully diluted

LineSharesAs of
Common shares33,461,450Nov 2, 2026

Share count over time

CountShares
Nov 2, 202633,461,450
Sep 30, 202633,457,450

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.8.02M24.0%US$209MSep 30, 2026
NEA Management Company, LLC7.39M22.1%US$192MSep 30, 2026
Sands Capital Alternatives, LLC2.5M7.5%US$65MSep 30, 2026
Samsara Biocapital, LLC2.11M6.3%US$54.9MSep 30, 2026
JPMorgan1M3.0%US$25.5MSep 30, 2026
T. Rowe Price926K2.8%US$24.1MSep 30, 2026
Vanguard786K2.3%US$20.4MSep 30, 2026
Vestal Point Capital, LP640K1.9%US$16.6MSep 30, 2026
BlackRock630K1.9%US$16.4MSep 30, 2026
abrdn507K1.5%US$13.2MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Millennium419K1.3%US$10.9MSep 30, 2026
Geode Capital237K0.71%US$6.17MSep 30, 2026
Franklin Templeton233K0.70%US$8.04MSep 30, 2026
State Street177K0.53%US$4.6MSep 30, 2026
TD76,9800.23%US$1.96MSep 30, 2026
Goldman Sachs72,3210.22%US$1.88MSep 30, 2026
Schwab70,7380.21%US$1.84MSep 30, 2026
Northern Trust65,2250.19%US$1.7MSep 30, 2026
Ameriprise57,3570.17%US$1.49MSep 30, 2026
Verdad Advisers, LP56,7080.17%US$1.47MSep 30, 2026
Manufacturers Life Insurance Company, The45,9390.14%US$1.19MSep 30, 2026
Alps Advisors Inc44,3020.13%US$1.15MSep 30, 2026
Propel Bio Management, LLC41,4180.12%US$1.08MSep 30, 2026
Russell Investments Group, Ltd.38,9440.12%US$1.01MSep 30, 2026
Wellington37,4020.11%US$972KSep 30, 2026
Morgan Stanley30,3140.09%US$788KSep 30, 2026
UBS29,8500.09%US$776KSep 30, 2026
BNY22,6200.07%US$588KSep 30, 2026
Virtus Investment Advisers, LLC17,2090.05%US$447KSep 30, 2026
Rhumbline Advisers12,2250.04%US$318KSep 30, 2026
Nuveen11,9610.04%US$311KSep 30, 2026
Marshall Wace, LLP11,9050.04%US$310KSep 30, 2026
Bank of America10,0330.03%US$261KSep 30, 2026
Gsa Capital Partners LLP8,4310.03%US$219KSep 30, 2026
XTX Topco Ltd8,3890.03%US$218KSep 30, 2026
DWS7,9310.02%US$206KSep 30, 2026
Invesco7,7360.02%US$201KSep 30, 2026
MetLife Investment Management, LLC6,9860.02%US$182KSep 30, 2026
New York State Common Retirement Fund5,4000.02%US$140KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.4,4170.01%US$115KSep 30, 2026
Barclays3,5400.01%US$92,040Sep 30, 2026
Police & Firemen's Retirement System of New Jersey3,268<0.01%US$84,968Sep 30, 2026
Wells Fargo2,491<0.01%US$64,766Sep 30, 2026
BNP Paribas2,254<0.01%US$58,604Sep 30, 2026
Ameritas Investment Partners, Inc.1,006<0.01%US$26,156Sep 30, 2026
RBC981<0.01%US$26,000Sep 30, 2026
Legal & General846<0.01%US$21,949Sep 30, 2026
Fidelity728<0.01%US$18,928Sep 30, 2026
Aster Capital Management (DIFC) Ltd598<0.01%US$15,548Sep 30, 2026
Tower Research Capital LLC (TRC)561<0.01%US$14,586Sep 30, 2026

This page holds 50 of 67 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund317K0.95%US$7.06MJun 30, 2026
JPMorgan Small Cap Growth Fund291K0.87%US$6.48MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.247K0.74%US$5.5MJun 30, 2026
iShares Russell 2000 ETF239K0.71%US$5.31MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.230K0.69%US$5.11MJun 30, 2026
Fidelity Small Cap Index Fund121K0.36%US$2.73MJul 31, 2026
Vanguard Extended Market Index Fund108K0.32%US$2.4MJun 30, 2026
JPMorgan Small Cap Blend Fund92,5810.28%US$2.06MJun 30, 2026
Franklin Biotechnology Discovery Fund84,7080.25%US$1.91MJul 31, 2026
iShares Russell 2000 Growth ETF71,6640.21%US$1.6MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund50,4790.15%US$972KMay 31, 2026
Multi-Manager Small Cap Equity Strategies Fund46,1640.14%US$889KMay 31, 2026
Schwab U.S. Small-Cap ETF45,9510.14%US$885KMay 31, 2026
iShares Micro-Cap ETF37,1330.11%US$827KJun 30, 2026
iShares Russell 2000 Value ETF33,2670.10%US$741KJun 30, 2026
Schwab Small-Cap Index Fund26,8630.08%US$605KJul 31, 2026
Fidelity Total Market Index Fund22,9690.07%US$442KMay 31, 2026
Master Small Cap Index Series20,7150.06%US$461KJun 30, 2026
Fidelity Nasdaq Composite Index Fund18,9400.06%US$365KMay 31, 2026
T. Rowe Price Health Sciences Portfolio17,4500.05%US$388KJun 30, 2026
Virtus Biotech Clinical Trials Etf16,8550.05%US$380KJul 31, 2026
Fidelity Series Total Market Index Fund14,8770.04%US$287KMay 31, 2026
U.S. Small Cap Equity Fund14,7480.04%US$332KJul 31, 2026
Nuveen Small Cap Blend Index Fund14,6490.04%US$330KJul 31, 2026
EQ/2000 Managed Volatility Portfolio11,4600.03%US$255KJun 30, 2026
LVIP State Street Small-Cap Index Fund8,3000.02%US$185KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund7,2720.02%US$162KJun 30, 2026
Schwab Total Stock Market Index Fund7,2000.02%US$162KJul 31, 2026
Fidelity Small Cap Growth Index Fund7,1220.02%US$159KJun 30, 2026
Health Sciences Trust5,9920.02%US$133KJun 30, 2026
Schwab U.S. Broad Market ETF5,7000.02%US$110KMay 31, 2026
Vanguard Balanced Index Fund5,4040.02%US$120KJun 30, 2026
Global X Russell 2000 ETF5,2910.02%US$119KJul 31, 2026
Small Cap Index Fund5,2170.02%US$116KJun 30, 2026
Fidelity Small Cap Value Index Fund4,8510.01%US$108KJun 30, 2026
EQ/T.Rowe Price Health Sciences Portfolio4,2140.01%US$93,804Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund3,9820.01%US$88,639Jun 30, 2026
MetLife Russell 2000 Index Portfolio3,9590.01%US$88,127Jun 30, 2026
Vanguard Russell 2000 Index Fund3,259<0.01%US$62,768May 31, 2026
ATM Small Cap Managed Volatility Portfolio3,212<0.01%US$71,499Jun 30, 2026
Small-Cap Index Portfolio3,106<0.01%US$69,140Jun 30, 2026
1290 VT Micro Cap Portfolio2,472<0.01%US$55,027Jun 30, 2026
NVIT Small Cap Index Fund2,416<0.01%US$53,780Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund2,036<0.01%US$45,871Jul 31, 2026
DWS Small Cap Index VIP1,747<0.01%US$38,888Jun 30, 2026
T. Rowe Price Small-Cap Index Fund1,690<0.01%US$37,619Jun 30, 2026
Victory Extended Market Index Fund1,609<0.01%US$36,251Jul 31, 2026
BlackRock Small Cap Index V.I. Fund1,454<0.01%US$32,366Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio1,321<0.01%US$29,405Jun 30, 2026
SA Small Cap Index Portfolio1,298<0.01%US$29,244Jul 31, 2026

This page holds 50 of 77 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Ra Capital Management, L.P.
Director, 10% owner
Buy1,000USD 32.43US$32,430Nov 16, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.24.10%8.02MFeb 9, 2026Schedule 13D
New Enterprise Associates 17, L.P.22.20%7.39MFeb 9, 2026Schedule 13D
Vensana Capital I GP, LLC8.90%2.98MNov 16, 2026Schedule 13D
SANDS FRANK M.7.80%2.5MFeb 6, 2026Schedule 13G
Gilde Healthcare Holding B.V.6.57%2.19MFeb 9, 2026Schedule 13D
Srinivas Akkaraju6.30%2.11MFeb 9, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Feb 5, 2026
Ali Behbahani
Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past)
Director · Since at least Feb 5, 2026
Habib Joseph Dable
Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past)
Director · Since at least Feb 5, 2026
Geoffrey B Pardo
Other companies: Shoulder Innovations, Inc. (Director · Since at least Jul 30, 2025); CVRx, Inc. (Director · Jun 29, 2021 – Jul 2, 2021 · Past); Inari Medical Inc (Director · May 21, 2020 – May 27, 2020 · Past); Vapotherm Inc (Director · Nov 13, 2018 – Jul 24, 2019 · Past)
Director · Since at least Feb 5, 2026
Michael Dybbs
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Sutro Biopharma, Inc. (Member, Board of Directors · Since at least Sep 26, 2018); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past)
Director · Since at least Feb 5, 2026
Elizabeth G. O’Farrell
Other companies: LENSAR, Inc. (Director · Since at least May 25, 2022); Geron Corporation (Director · Since at least May 10, 2022); Inhibikase Therapeutics, Inc. (Director · Jun 24, 2022 – Jun 24, 2022 · Past)
Director · Since at least Feb 5, 2026
Zach Scheiner
Other companies: LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Nkarta, Inc. (Member of Board of Directors · Since at least Jul 9, 2020)
Director · Since at least Feb 5, 2026
Kirk Nielsen
Other companies: CVRx, Inc. (Director · Since at least May 12, 2025)
Director · Since at least Feb 5, 2026
Anand SundaramVice President, Head of Commercial · Since at least Nov 4, 2026
Bilal Arshad KhanDirector · Since at least Feb 5, 2026
All 23 people
PersonSeat
Brian AukshunasVice President, Finance · Since at least Nov 4, 2026
Chetan PujaraChief R&D Officer · Since at least Feb 5, 2026
James DennewillChief Operating Officer · Since at least Aug 28, 2026
James Robert Dennewill JrChief Operating Officer · Since at least Feb 5, 2026
Jean-Frédéric ViretChief Financial Officer · Since at least Mar 26, 2026
Laurie MellottVice President, Clinical Operations · Since at least Nov 4, 2026
Malik Y. KahookCo-founder, President, Chief Medical Officer, and Executive Chair of the Board · Since at least Feb 5, 2026
Mike PinderVice President, Marketing · Since at least Jun 2, 2026
Nina NguyenSenior Vice President, Regulatory & Quality · Since at least Nov 4, 2026
Patrick MooneyChief Executive Officer, Director · Since at least Feb 5, 2026
Paul YooSenior Vice President, Clinical Development · Since at least Oct 19, 2026
Rachel GiletteVice President, Human Resources · Since at least Nov 4, 2026
Shannon TreviñoGeneral Counsel · Since at least Jun 15, 2026

Open People

Log in to ask 6ix AI your own questions about SpyGlass Pharma, Inc.